Page last updated: 2024-09-05

lenalidomide and Colonic Inertia

lenalidomide has been researched along with Colonic Inertia in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ikeda, T; Kimura, F; Okamura, I; Sato, K1
Cole, C; Ervin-Haynes, A; Justice, G; Kaplan, H; Moore, T; Pietronigro, D; Reeder, C; Takeshita, K; Voralia, M; Vose, JM; Wiernik, PH; Witzig, TE; Zeldis, JB1
Anderson, KC; Balinski, K; Catley, LP; Chauhan, D; Davies, F; Deocampo, R; Doss, D; Freeman, A; Hideshima, T; Kelly, K; LeBlanc, R; McKenney, M; Mechlowicz, J; Mitsiades, C; Rich, R; Richardson, PG; Ryoo, JJ; Schlossman, RL; Weller, E; Zeldis, J1
Tariman, JD1

Reviews

1 review(s) available for lenalidomide and Colonic Inertia

ArticleYear
Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
    Clinical journal of oncology nursing, 2007, Volume: 11, Issue:4

    Topics: Anorexia; Antineoplastic Agents; Apoptosis; Constipation; Diarrhea; Drug Eruptions; Drug Monitoring; Dyspnea; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Nurse's Role; Nursing Assessment; Oncology Nursing; Thalidomide; Thrombocytopenia; Thromboembolism; Treatment Failure

2007

Trials

2 trial(s) available for lenalidomide and Colonic Inertia

ArticleYear
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Constipation; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Recurrence; Thalidomide; Time Factors; Treatment Outcome

2009
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
    Blood, 2002, Nov-01, Volume: 100, Issue:9

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Combined Modality Therapy; Constipation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Myeloma Proteins; Nervous System Diseases; Neutropenia; Peripheral Blood Stem Cell Transplantation; Remission Induction; Safety; Salvage Therapy; Thalidomide; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome

2002

Other Studies

1 other study(ies) available for lenalidomide and Colonic Inertia

ArticleYear
[Thalidomide-associated hypothyroidism in a patient with multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2015, Volume: 56, Issue:1

    Topics: Aged; Constipation; Humans; Hypothyroidism; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Thyroid Function Tests

2015